Stocks Health care INDP
NASDAQ · Health careIndaptus Therapeutics, Inc. (INDP)
It posted a net loss of $15.4M. At June 30, 2026 it held $7.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Indaptus Therapeutics, Inc.
- Net worth
- Indaptus Therapeutics, Inc. has a market value (market cap) of $417M at the latest share price, and shareholders' equity of $11.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $14.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Indaptus Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Indaptus Therapeutics, Inc. does
Indaptus Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INDP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$20.8M | -$21.58 | n/a |
| 2024 | n/a | -$15M | -$44.96 | n/a |
| 2023 | n/a | -$15.4M | -$51.10 | n/a |
| 2022 | n/a | -$14.3M | -$48.31 | n/a |
| 2021 | n/a | -$7.7M | -$52.78 | -$11.3M |
| 2021 | n/a | -$3.6M | -$51.38 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Indaptus Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 22, 2026Activist stake changed SCHEDULE 13D/A
- October 22, 2026Activist stake changed SCHEDULE 13D/A
- October 22, 2026Activist stake changed SCHEDULE 13D/A
- October 21, 2026Activist stake changed SCHEDULE 13D/A
- October 20, 2026Other event 8-K
- October 5, 2026
- September 30, 2026Material agreement8-KIndaptus Therapeutics has extended the closing deadline for its private placement to October 16, 2026.
- September 10, 2026
- September 8, 2026Material agreement 8-K/A
- September 4, 2026
Insider trades
What the people running Indaptus Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 20, 2026 | Ben-Tzvi AvrahamDirector | Received as pay | 25,000 | - |
| December 22, 2025 | Linscott Walt AddisonChief Operating Officer | Received as pay | 54,421 | $110.5K |
| December 22, 2025 | Newman Michael JamesCSO and Director, Director | Received as pay | 52,204 | $106K |
| December 22, 2025 | Meckler Jeffrey ACo-Chief Executive Officer, Director, 10% owner | Received as pay | 216,617 | $439.7K |
| December 22, 2025 | Sassi NirChief Financial Officer | Received as pay | 26,758 | $54.3K |
Who owns INDP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lazar David E.13D, may seek influence | 47.93% | March 24, 2026 |
| Yao Yun13D, may seek influence | 27.34% | October 22, 2026 |
| Sino Lion Ventures Ltd13D, may seek influence with 1 related filers | 25.33% | October 22, 2026 |
| Jeffery A. Meckler13D, may seek influence | 12.7% | December 30, 2025 |
| Dai Junyi13D, may seek influence | 7.33% | October 22, 2026 |
| Jeffrey A. Meckler13D, may seek influence | 6.9% | November 26, 2024 |
| Yang Ting13D, may seek influence | 6.48% | October 21, 2026 |
| Newman Michael James13D, may seek influence | 5.4% | December 30, 2025 |
Largest institutional holders
Insiders
5 insiders reported holding 437,287 shares in total, about $1.4M at the last price.
| Holder | Shares |
|---|---|
| Meckler Jeffrey ACo-Chief Executive Officer, Director, 10% owner | 229,929 |
| Newman Michael JamesCSO and Director, Director | 101,074 |
| Linscott Walt AddisonChief Operating Officer | 54,426 |
| Sassi NirChief Financial Officer | 26,758 |
| Ben-Tzvi AvrahamDirector | 25,100 |
Questions about INDP
What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as INDP. Its shares trade on NASDAQ under the ticker INDP.
What is Indaptus Therapeutics, Inc.'s net worth?
Indaptus Therapeutics, Inc. has a market value (market cap) of $417M at the latest share price, and shareholders' equity of $11.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Indaptus Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $15.4M.
When did Indaptus Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from October 22, 2026.
When is Indaptus Therapeutics, Inc.'s next earnings report?
Indaptus Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INDP with
Follow INDP
Get an email when Indaptus Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Indaptus Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.